U.S. Equity News: MedImmune Licenses Reverse Genetics Technology and Amylin Could Make Major Investment in West Chester.

(From M2 Presswire)

City of Industry, CA - Biotechnology industry alert provided by U.S. Equity News. MedImmune, Inc. (Nasdaq: MEDI) recently announced that it has licensed its proprietary reverse genetics intellectual property to sanofi pasteur, the vaccines business of the sanofi-aventis Group, to support the development and construction of new vaccine strains to produce human seasonal, pre-pandemic and pandemic influenza vaccines. Reverse genetics is a method by which viruses such as influenza can be generated entirely from segments of DNA. Shares of biopharmaceutical company CV Therapeutics Inc. (Nasdaq:CVTX) fell Wednesday continuing a topsy-turvy week of …